A new experimental treatment may have found a way to outsmart glioblastoma’s toughest defense: the blood-brain barrier. Researchers used sugar-coated nanoparticles to ferry genetic instructions that restore a key tumor-suppressing protein directly into brain cancer cells. In mouse studies, the therapy increased median survival by 50% while shrinking tumors without noticeable damage to other organs.
Animal models have long been central to neuroscience, providing direct experimental access to neural processes underlying perception, action, cognition, and disease. Over the past century, work in non-human primates (NHPs), rodents, and other species has established key principles of neural organization and behavior and has supported much of translational neuroscience. However, the institutional and material conditions that sustain animal-based research are now changing in fundamental ways. Ethical and regulatory requirements have intensified, costs and approval timelines have increased, and global supply chains, particularly for NHPs, have become fragile. In parallel, advances in human neuroscience, stem-cell-derived systems, and computational approaches have matured to the point that they challenge the historical reliance on animals for many classes of questions. These forces are not eliminating animal research, but they are reshaping the conditions under which it remains feasible, competitive, and scientifically justified. In this Perspective, we examine how these converging pressures are reconfiguring animal-based neuroscience. We review long-term trends in animal use and accessibility, highlighting species-specific constraints and emerging geopolitical asymmetries. We then analyze the growing role of alternative and complementary platforms, including human brain organoids, genetically engineered rodents, small primates, and ‘human-centric’ neurophysiological and imaging approaches, emphasizing both their strengths and limitations. Finally, we discuss the implications of this diversification for research planning, training, and scientific organization. We argue that the future of neuroscience will be defined not by the disappearance of animal models, but by their integration into hybrid experimental frameworks that preserve mechanistic rigor while adapting to evolving scientific and societal constraints.
Keywords: animal models; neuroscience methodology; alternative experimental platforms; translational validity; research ethics and regulation.
While GLP-1 drugs can curb cardiometabolic dysfunction, reducing the risk of life-limiting and life-threatening diseases that would otherwise shorten health and lifespan, mechanistic evidence that they directly influence the biology of aging remains limited.
Can GLP-1 drugs rewind the epigenetic clock?
UCSD researchers conducted a post hoc analysis of a Phase 2b clinical trial evaluating the use of semaglutide in human immunodeficiency virus (HIV)-associated lipohypertrophy (HALS).
(H2O), the principal component of living organisms including humans, dissociates into H+ and OH-in aqueous environments, and the resulting H+ concentration determines both cellular pH and the proton motive force (PMF) across cellular membranes. These physicochemical parameters are fundamental regulators of a wide range of biological processes. Optogenetics enables the manipulation of biological and cellular functions using light, typically through the ectopic expression of microbial rhodopsins as photoreceptive proteins in target cells or organs.
Occasionally, the sun unleashes powerful flares and coronal mass ejections, which hurl plasma and energetic particles into space. On the infant Earth, this solar activity drove cascades of atmospheric chemical reactions that may have helped form the building blocks of life. More recently, scientists have discovered that applying plasma to seeds in a controlled way can trigger similar activity, making them faster-growing and more resilient. Researchers at Nagoya University and Kyushu University in Japan have compiled a comprehensive review of this new field—termed “plasma agriculture”—as a potential sustainable solution to address global food shortages.
The word plasma brings to mind a hot, ionized inferno that makes up the fourth state of matter. But the plasma used here is different. By applying high voltage to air or any gas, electrons are stripped from a tiny fraction of its molecules and gain very high energies. These electrons zipping around can effectively mimic the behavior of plasma even though the bulk of the gas remains at room temperature.
This low-temperature plasma can be applied directly to seeds without burning them. Excessive use of chemicals and genetic modification of plants cause concern for many people. Instead, plasma agriculture can offer similarly high crop yields without invasive intervention.
The combination drug ceftazidime-avibactam (CZA) is a last line of defense against the common Pseudomonas aeruginosa hospital bug: It’s the drug that gets called in when nothing else works, but there’s now evidence that it may not keep working for long.
Based on an analysis of two critically ill patients with P. aeruginosa infections, the bacteria are developin g genetic mutations that change the enzymes they produce – and can ward off an attack from CZA.
Researchers led by a team from Tongji University in China have now published a new paper in Microbiology Spectrum detailing the mutations and what it might mean for fighting P. aeruginosa in the future.
A study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), working in collaboration with an international research team, has identified a new molecular mechanism involved in hypertrophic cardiomyopathy, the most common inherited cardiovascular disease.
The research, published in Nature Cardiovascular Research, also demonstrates that mavacamten—the first targeted therapy available for this condition—is effective across different types of genetic mutations.
Hypertrophic cardiomyopathy is the most common inherited heart disease and the leading cause of sudden cardiac death in young people and athletes.